Cargando…

The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012

Neuroendocrine tumors (NETs) comprise a heterogeneous group of tumors that form a distinct entity. Approximately 75–80% of patients present with liver metastases at the time of their diagnosis, and 20%–25% will develop these lesions in the course of their disease. The presence of secondary deposits...

Descripción completa

Detalles Bibliográficos
Autores principales: Macedo, Daniela, Amaral, Teresa, Fernandes, Isabel, Sousa, Ana Rita, Costa, Ana Lúcia, Távora, Isabel, Quintela, António, Cortes, Paulo, Costa, Luís
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890909/
https://www.ncbi.nlm.nih.gov/pubmed/27335831
http://dx.doi.org/10.1155/2013/702167
_version_ 1782435182174797824
author Macedo, Daniela
Amaral, Teresa
Fernandes, Isabel
Sousa, Ana Rita
Costa, Ana Lúcia
Távora, Isabel
Quintela, António
Cortes, Paulo
Costa, Luís
author_facet Macedo, Daniela
Amaral, Teresa
Fernandes, Isabel
Sousa, Ana Rita
Costa, Ana Lúcia
Távora, Isabel
Quintela, António
Cortes, Paulo
Costa, Luís
author_sort Macedo, Daniela
collection PubMed
description Neuroendocrine tumors (NETs) comprise a heterogeneous group of tumors that form a distinct entity. Approximately 75–80% of patients present with liver metastases at the time of their diagnosis, and 20%–25% will develop these lesions in the course of their disease. The presence of secondary deposits in the liver significantly increases the morbidity and mortality in these patients. The only potentially curative treatment is the surgical resection of the primary tumor and hepatic lesions. However, only 10% of patients presents under ideal conditions for that approach. Several techniques aimed at localized liver lesions have been applied also with interesting results in terms of survival and symptom control. The same has been demonstrated with new systemic therapies (target therapies). However, these are still under study, in order to define their true role in the management of these patients. This paper intends to address, in a general way, the various treatment options in patients with liver metastases from neuroendocrine tumors.
format Online
Article
Text
id pubmed-4890909
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-48909092016-06-22 The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012 Macedo, Daniela Amaral, Teresa Fernandes, Isabel Sousa, Ana Rita Costa, Ana Lúcia Távora, Isabel Quintela, António Cortes, Paulo Costa, Luís ISRN Hepatol Review Article Neuroendocrine tumors (NETs) comprise a heterogeneous group of tumors that form a distinct entity. Approximately 75–80% of patients present with liver metastases at the time of their diagnosis, and 20%–25% will develop these lesions in the course of their disease. The presence of secondary deposits in the liver significantly increases the morbidity and mortality in these patients. The only potentially curative treatment is the surgical resection of the primary tumor and hepatic lesions. However, only 10% of patients presents under ideal conditions for that approach. Several techniques aimed at localized liver lesions have been applied also with interesting results in terms of survival and symptom control. The same has been demonstrated with new systemic therapies (target therapies). However, these are still under study, in order to define their true role in the management of these patients. This paper intends to address, in a general way, the various treatment options in patients with liver metastases from neuroendocrine tumors. Hindawi Publishing Corporation 2013-02-14 /pmc/articles/PMC4890909/ /pubmed/27335831 http://dx.doi.org/10.1155/2013/702167 Text en Copyright © 2013 Daniela Macedo et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Macedo, Daniela
Amaral, Teresa
Fernandes, Isabel
Sousa, Ana Rita
Costa, Ana Lúcia
Távora, Isabel
Quintela, António
Cortes, Paulo
Costa, Luís
The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012
title The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012
title_full The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012
title_fullStr The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012
title_full_unstemmed The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012
title_short The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012
title_sort treatment of liver metastases in patients with neuroendocrine tumors in 2012
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890909/
https://www.ncbi.nlm.nih.gov/pubmed/27335831
http://dx.doi.org/10.1155/2013/702167
work_keys_str_mv AT macedodaniela thetreatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012
AT amaralteresa thetreatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012
AT fernandesisabel thetreatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012
AT sousaanarita thetreatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012
AT costaanalucia thetreatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012
AT tavoraisabel thetreatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012
AT quintelaantonio thetreatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012
AT cortespaulo thetreatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012
AT costaluis thetreatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012
AT macedodaniela treatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012
AT amaralteresa treatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012
AT fernandesisabel treatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012
AT sousaanarita treatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012
AT costaanalucia treatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012
AT tavoraisabel treatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012
AT quintelaantonio treatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012
AT cortespaulo treatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012
AT costaluis treatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012